Hansa Biopharma ABOSTO:HNSA -0.34%50 Days Payable is 357.98 as of Mar. 2026, which is 90% below its 10-year median of 3,619.67. GuruFocus rates OSTO:HNSA with a GF Score™ of 50/100 and a GF Value™ of kr24.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 702 Biotechnology companies, Hansa Biopharma AB ranks better than 64.81% on this metric.
The historical rank and industry rank for Hansa Biopharma AB's Days Payable or its related term are showing as below:
OSTO:HNSA'
s Days Payable Range Over the Past 10 Years
Min: 200.23 Med: 3619.67 Max: 19177.04
Current: 217.83
During the past 13 years, Hansa Biopharma AB's highest Days Payable was 19177.04. The lowest was 200.23. And the median was 3619.67.
OSTO:HNSA's Days Payable is ranked better than 64.81% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs OSTO:HNSA: 217.83
Hansa Biopharma AB's Days Payable
increased
from Mar. 2025 (167.36) to Mar. 2026 (357.98).
It may suggest that Hansa Biopharma ABdelayed paying its suppliers.
Hansa Biopharma AB Days Payable Related Terms
Hansa Biopharma AB Days Payable Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hansa Biopharma AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (OSTO:HNSA) has a Days Payable of 357.98 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hansa Biopharma AB and its competitors. This is 90% below median its historical median of 3,619.67. Over the past decade, Hansa Biopharma AB's Days Payable has ranged from 200.23 to 19,177.04. According to the industry distribution chart, Hansa Biopharma AB ranks #247 out of 702 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Hansa Biopharma AB's Days Payable too high?
Hansa Biopharma AB's current Days Payable of 357.98 is 90% below median its 10-year median of 3,619.67. Over the past 10 years, this metric has ranged from a low of 200.23 to a high of 19,177.04. The Biotechnology industry median Days Payable is 113.56. Hansa Biopharma AB's value of 357.98 is 215.2% above this industry median. Based on the distribution chart, Hansa Biopharma AB ranks #247 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hansa Biopharma AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #247 out of 702 companies for Days Payable. This puts Hansa Biopharma AB in the upper half of its industry. The industry median Days Payable is 113.56. Hansa Biopharma AB's value of 357.98 is 215.2% above this benchmark. Historically, Hansa Biopharma AB's own Days Payable has ranged from 200.23 to 19,177.04 over the past decade. While the company's 10-year median is 3,619.67 vs. the industry median of 113.56, Hansa Biopharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansa Biopharma AB's current Days Payable of 357.98 is 215.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hansa Biopharma AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current Days Payable is 357.98, which is 90% below median its own 10-year median of 3,619.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.51, compared to a current price of kr34.88 — trading 42.3% above its estimated fair value. The current Days Payable is 357.98, which is 90% below median its 10-year median of 3,619.67 and 215.2% above the Biotechnology industry median of 113.56. Hansa Biopharma AB's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Days Payable is 357.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr34.88 is trading 42.3% above its estimated GF Value™ of kr24.51.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Days Payable: 357.98 (90% below median its 10-year median of 3,619.67)
GF Value™: kr24.51 vs. price of kr34.88 (42.3% above fair value)
Industry Position: 215.2% above the Biotechnology median (#247 of 702)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
50GF Score
Get the complete analysis for OSTO:HNSA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
